Efficacy and safety of oral vitamin D (cholecalciferol) supplement therapy in Stage I primary hypertension; a prospective, randomized, double-blind, placebo controlled, clinical trial in a tertiary care hospital in central India.

Manali Mahajan, Swapnil Deshmukh, Sujata Dudhgaonkar


Introduction: Hypertension is one of the most common cardiovascular disorders. Almost all targets in its therapy are exploited and there is a growing need to search for newer targets. Vitamin D is gaining increasing attention in treatment of primary hypertension.

Objectives: To study the efficacy and safety of Vitamin D supplementation on systolic and diastolic BP in patients of primary hypertension (JNC 7 stage I) receiving conventional antihypertensive medications (namely Tab atenolol 50mg or Tab amlodipine 5mg).

Methods: It was a prospective, randomized, double blind, parallel, placebo controlled clinical trial with 2 groups of 33 patients each. Both groups had patients receiving conventional antihypertensives (Tab atenolol50mg or Tab amlodipine 5mg). Group A patients were given placebo (lactose tablets) and Group B were given oral Vitamin D3 (60,000 IU) once weekly at bedtime after meals, repeated every fortnightly for 12 weeks.

Results: Patients belonging to Group B showed a statistically significant (p < 0.0001) decline in both systolic blood pressure after 12 weeks of receiving vitamin D supplementation. There was no significant change in the safety parameters.

Conclusions: Thus, our study shows that Vitamin D supplementation has some role in safely reducing systolic blood pressure after 12 weeks of supplementation and hence it should be supplemented with antihypertensive drugs to the patients with hypertension.


Vitamin D, Hypertension, Amlodipine, Atenolol

Full Text:


DOI: https://doi.org/10.7439/ijpr.v7i6.4206

Copyright (c) 2017 International Journal of Pharmacological Research

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.